Open Access

β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib

  • Authors:
    • Cuicui Wu
  • View Affiliations

  • Published online on: May 12, 2022     https://doi.org/10.3892/ol.2022.13326
  • Article Number: 205
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although bortezomib (BTZ) displays efficacy in treating multiple myeloma (MM), BTZ resistance in MM patients has been reported. Meanwhile, treating BTZ resistant MM cells with β‑catenin inhibitors have demonstrated the ability to reserve BTZ resistance. Thus, the present study aimed to investigate the synergistic effect of the β‑catenin inhibitors, ICG‑001 and pyrvinium (PP), with BTZ in the treatment of BTZ‑resistant MM cells. Different concentrations of ICG‑001 (0‑32 µM) or PP (0‑32 nM) were used to treat the BTZ‑resistant RPMI‑8226 (RPMI‑8226BR) and BTZ‑resistant KMS‑11 (KMS‑11BR) cell lines, followed by a BTZ combination treatment. Subsequently, cell viability and apoptosis in these two cell lines were determined by CCK‑8 assay and flow cytometry, respectively. The proteins involved in the Wnt/β‑catenin signaling pathway were detected using western blotting. The Wnt/β‑catenin signaling pathway was activated in the RPMI‑8226BR and the KMS‑11BR cells. In addition, the cell viability of RPMI‑8226BR and KMS‑11BR cells were decreased following β‑catenin inhibitor (ICG‑001 and PP) treatment alone. Furthermore, the β‑catenin inhibitors, ICG‑001 and PP, plus BTZ combination treatment revealed a notable decrease in cell viability and a marked increase in cell apoptosis rate, compared with that in cells treated with ICG‑001, PP or BTZ alone in the RPMI‑8226BR and KMS‑11BR cell lines. In conclusion, the β‑catenin inhibitors, ICG‑001 and PP not only increased apoptosis, but also sensitized BTZ‑resistant MM cells to BTZ, indicating their potential therapeutic application in MM.
View Figures
View References

Related Articles

Journal Cover

July-2022
Volume 24 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu C: β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib. Oncol Lett 24: 205, 2022
APA
Wu, C. (2022). β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib. Oncology Letters, 24, 205. https://doi.org/10.3892/ol.2022.13326
MLA
Wu, C."β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib". Oncology Letters 24.1 (2022): 205.
Chicago
Wu, C."β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib". Oncology Letters 24, no. 1 (2022): 205. https://doi.org/10.3892/ol.2022.13326